Table 2.
Characteristics of patient cohorts and oncologists by scenario and industry payment. Values are number (percentage) unless stated otherwise
| Characteristics | CSPC (n=9799) | GCSF (n=271 485) | Nab-paclitaxel (n=86 394) | Branded drug (n=13 386) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Paid (n=2962) | Not paid (n=6837) | Paid (n=76 747) | Not paid (n=194 738) | Paid (n=18 491) | Not paid (n=67 903) | Paid (n=4170) | Not paid (n=9216) | ||||
| Patient cohorts | |||||||||||
| Cancer type: | |||||||||||
| Breast | 0 | 0 | 21 816 (28.4) | 54 510 (28.0) | 7293 (39.4) | 24 682 (36.3) | 245 (5.9) | 1099 (11.9) | |||
| Colon | 0 | 0 | 16 482 (21.5) | 25 188 (12.9) | 0 | 0 | 143 (3.4) | 366 (4.0) | |||
| Myeloid leukemia | 0 | 0 | 0 | 0 | 0 | 0 | 678 (16.3) | 796 (8.6) | |||
| Lung | 0 | 0 | 33 532 (43.7) | 95 696 (49.1) | 11 198 (60.6) | 43 221 (63.7) | <11 | 156 (1.7) | |||
| Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 3056 (73.3) | 6614 (71.8) | |||
| Non-Hodgkin’s lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | <11 | 19 (0.2) | |||
| Prostate | 2962 (100) | 6837 (100) | 0 | 0 | 0 | 0 | <11 | 46 (0.5) | |||
| Rectum | 0 | 0 | 4917 (6.4) | 19 344 (9.9) | 0 | 0 | 32 (0.8) | 120 (1.3) | |||
| Median age (years) | 76 | 75 | 72 | 72 | 72 | 72 | 73 | 73 | |||
| Sex: | |||||||||||
| Female | 0 | 0 | 48 276 (62.9) | 121 995 (62.6) | 12 129 (65.6) | 43 810 (64.5) | 2093 (50.2) | 4749 (51.5) | |||
| Male | >2950 (>99.9)* | >6820 (>99.9)* | 28 439 (37.1) | 72 647 (37.3) | >6340 (>34.3)* | 24 066 (35.4) | 2077 (49.8) | >4450 (>48.3)* | |||
| Unknown | <11 | <11 | 32 (<0.1) | 96 (<0.1) | <11 | 27 (0.0) | 0 | <11 | |||
| Median zip code income ($) | 59 655 | 62 862 | 58 137 | 61 402 | 58 569 | 60 257 | 60 349 | 62 272 | |||
| Mean No of comorbidities | 11.2 | 11.0 | 12.7 | 12.6 | 13.0 | 12.8 | 12.4 | 11.6 | |||
| Index year: | |||||||||||
| 2014 | 464 (15.7) | 973 (14.2) | 15 996 (20.8) | 36 457 (18.7) | 4553 (24.6) | 12 749 (18.8) | 0 | 0 | |||
| 2015 | 469 (15.8) | 1063 (15.5) | 14 657 (19.1) | 34 529 (17.7) | 4058 (21.9) | 12 134 (17.9) | 0 | 0 | |||
| 2016 | 535 (18.1) | 1201 (17.6) | 13 578 (17.7) | 32 714 (16.8) | 3424 (18.5) | 11 737 (17.3) | 221 (5.3) | 178 (1.9) | |||
| 2017 | 504 (17.0) | 1238 (18.1) | 11 917 (15.5) | 31 277 (16.1) | 2811 (15.2) | 10 756 (15.8) | 214 (5.1) | 215 (2.3) | |||
| 2018 | 554 (18.7) | 1215 (17.8) | 11 494 (15.0) | 31 094 (16.0) | 2298 (12.4) | 10 870 (16.0) | 2093 (50.2) | 3318 (36.0) | |||
| 2019 | 436 (14.7) | 1147 (16.8) | 9105 (11.9) | 28 667 (14.7) | 1347 (7.3) | 9657 (14.2) | 1642 (39.4) | 5505 (59.7) | |||
| Oncologists | |||||||||||
| No of unique assigned oncologists | 5367 | 18 148 | 14 197 | 7409 | |||||||
| No of patients per oncologist: | |||||||||||
| Mean | 1.8 | 15.0 | 6.1 | 1.8 | |||||||
| Median | 1 | 11 | 4 | 1 | |||||||
| Median years since graduation | 26 | 24 | 25 | 24 | |||||||
| Sex: | |||||||||||
| Male | 4158 (77.5) | 11 652 (64.2) | 9243 (65.1) | 5214 (70.4) | |||||||
| Female | 1103 (20.6) | 5635 (31.1) | 4411 (31.1) | 2172 (29.3) | |||||||
| Unknown | 106 (2.0) | 861 (4.7) | 543 (3.8) | 23 (0.3) | |||||||
| Located at an NCCN Institution | 339 (6.3) | 1844 (10.2) | 1131 (8.0) | 552 (7.5) | |||||||
$
1.00 (£0.81; €0.94).
CSPC=castration sensitive prostate cancer; GCSF=granulocyte colony stimulating factors; NCCN=National Comprehensive Cancer Network.
*
Exact numbers masked to avoid identification.